The European Commission has granted marketing authorization to Sanofi and Regeneron Pharmaceuticals' Zaltrap (aflibercept) for previously treated metastatic colorectal cancer. Sanofi told Scrip it anticipates that the drug will be first available in Germany, Austria and the Nordic countries but would not comment further on its commercial strategy. Datamonitor analyst James Wade, however, believes that the commercial prospects for the drug may be limited.
Looking to the companies' additional plans for Zaltrap, Mr Wade believes that a label, expansion into the first-line CRC setting...
Welcome to Scrip
Create an account to read this article
Already a subscriber?